| Document |
Document Title |
|
WO/2022/131750A1 |
The present invention relates to: an L1 mutant peptide; a composition for alleviating, inhibiting, preventing or treating myopathy, obesity or diabetes, containing same as an active gradient; a method for alleviating, inhibiting, prevent...
|
|
WO/2022/131063A1 |
The purpose of the present invention is to provide a composition for improving muscle flexibility. The present invention relates to a composition for improving muscle flexibility that contains quercetin and/or a glycoside thereof.
|
|
WO/2022/131322A1 |
A purpose of the present invention is to develop and provide a neuron activator for activating brain neurons. Another purpose of the present invention is to provide an agent for accelerating, when cell transplantation is performed for a ...
|
|
WO/2022/122733A1 |
The present invention concerns a method of treating Duchenne muscular dystrophy (DMD) in a human, comprising systemically administering by intravascular injection a gene therapy product that comprises an adeno-associated viral (AAV) vect...
|
|
WO/2022/124626A1 |
The present invention relates to a method for selecting mesenchymal stem cells having improved self-maintenance ability, wherein mesenchymal stem cells having excellent self-proliferation ability can be selected to reduce donor variation...
|
|
WO/2022/122730A1 |
Compositions may be used for a variety of therapeutic applications, including treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, in particular in condition of oxidative stress, such ...
|
|
WO/2022/124345A1 |
Provided is an oligonucleotide which can induce the editing activity of ADAR in cells and has excellent stability in a living body. The oligonucleotide includes a first oligonucleotide specifying target RNA, and a second oligonucleotide ...
|
|
WO/2022/119974A1 |
Disclosed are RNA-targeting gene therapy compositions and methods for destroying or blocking toxic target CAG repeat RNA and treating CAG repeat disorders such as Huntington's Disease (HD) and Spinocerebellar Ataxia Type 1 (SCA1).
|
|
WO/2022/115919A1 |
The present disclosure relates to a formulation comprising tocotrienols and derivatives thereof, for transmucosal (such as buccal, sublingual and mucosal) administration.
|
|
WO/2022/119193A1 |
The present invention relates to a composition, for preventing, relieving or treating cancer cachexia or muscle loss, containing Uchasingi-hwan. The Uchasingi-hwan of the present invention exhibited a weight loss relieving effect in a ca...
|
|
WO/2022/118966A1 |
A purpose of the present invention is to provide an agent for promoting the uptake of nucleic acid molecules into cells. The present invention relates to, inter alia, an agent for promoting the uptake of nucleic acid molecules into cel...
|
|
WO/2022/120234A1 |
Various embodiments of a system and associated methods for facilitating a noninvasive stimulation protocol that targets corticospinal-motoneuronal synapses of multiple upper and lower limb muscles simultaneously using principles of spike...
|
|
WO/2022/117122A1 |
Provided is a use of a ferroptosis inhibitor in preparing a preparation for improving the motor function of a senescent individual. Transcriptome sequencing analysis has shown that TfR1 expression in skeletal muscle and muscle satellite ...
|
|
WO/2022/117012A1 |
The present invention relates to a spirocyclic JAK inhibitor, a pharmaceutical composition containing same, and an application thereof. Specifically, the present invention relates to a compound as shown in formula I or a stereoisomer or ...
|
|
WO/2022/098955A9 |
Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block ...
|
|
WO/2022/120132A1 |
Provided herein are oligonucleotide-antibody complexes, methods of preparing the complexes, and methods of using the complexes (e.g., treating muscle diseases). In particular, provided are compounds of Formula (I) and various methods for...
|
|
WO/2022/119979A1 |
Disclosed are RNA-targeting gene therapy compositions and methods for destroying or blocking toxic target CUG repeat RNA and treating DM1.
|
|
WO/2022/115347A1 |
Described are methods of improving muscle strength and mobility comprising administration of a fucosylated oligosaccharide.
|
|
WO/2022/114187A1 |
The present invention provides a compound for treating or preventing diseases caused by excessive mitochondrial divisions. The present invention relates to a compound represented by formula (1) (in the formula: R1 and R1' are each inde...
|
|
WO/2022/113693A1 |
A therapeutic agent for muscular dystrophy that includes a medium-chain triglyceride as an active ingredient.
|
|
WO/2022/114412A1 |
The present invention relates to: human skin-derived fibroblasts exhibiting a tendon regeneration effect; and a pharmaceutical composition for tendon regeneration and treatment, comprising same as an active ingredient. The fibroblasts de...
|
|
WO/2022/115353A1 |
Described are methods of reducing exercise-induced injury and/or enhancing muscle recovery after exercise in a subject by administering an effective amount of 2'-fucosyllactose (2'FL). Said effective amount will increases the subject's e...
|
|
WO/2022/112887A1 |
A method of treating acute nociceptive pain in mammals comprising: administering a therapeutically effective amount of a composition including a solution of Gonyautoxin 2 and Gonyautoxin 3 in a ratio of about 7:3 (GTX 2/3) to a subject i...
|
|
WO/2022/114138A1 |
Provided is a novel method for producing a (1R,2R,3R,5R,6R)-2-amino-6-fluoro-3-[(4-fluorophenyl)methoxy
]bicycle[3.1.0]hexane-2,6-dicarboxylic acid. This production method is characterized by relying on the conversion from a compound rep...
|
|
WO/2022/115745A1 |
Disclosed herein are products, methods, and uses for treating, ameliorating, udaying the progression of, and/or preventing a muscular dystrophy or a cancer including, but not limited to, facioscapulohumeral muscular dystrophy (FSHD) or a...
|
|
WO/2022/106615A1 |
The present disclosure relates generally to pharmaceutical compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-
2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase a...
|
|
WO/2022/106408A1 |
Composition comprising a combination of oleuropein or metabolite thereof and quercetin or derivative thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional ...
|
|
WO/2022/106407A1 |
Composition comprising a combination of oleuropein or metabolite thereof and nicotinamide riboside thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional su...
|
|
WO/2022/106566A1 |
Object of the present invention is an improved process for the preparation of Trenbolone Acetate of formula (I) having irregular hexagon plates crystal habit and/or a median value (D50) of the particle size distribution comprised in the ...
|
|
WO/2022/107146A1 |
The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject a pharmaceutical composition comprising pridopidine or pharmaceutical acceptable salts and at least one o...
|
|
WO/2022/104413A1 |
Provided herein are compositions, methods and kits for effectively preventing, treating, reducing, mitigating, or controlling female sexual interest and arousal disorder (FSIAD), wherein the method comprises administering to a subject in...
|
|
WO/2022/109595A1 |
The present disclosure relates generally to pharmaceutical compositions of N-(5-(5-((1R,2S)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-
2-methylphenyl)imidazo[1,2-a]pyridine-3-carboxamide useful as a selective inhibitor of c-kit kinase a...
|
|
WO/2022/102737A1 |
Provided is a pharmaceutical composition having edaravone as an active ingredient for oral administration or administration equivalent thereto. The pharmaceutical composition of the present invention contains edaravone as an active ing...
|
|
WO/2022/104069A1 |
The invention provides methods and compositions utilizing stromal vascular fraction derived from adipose tissue to treat various medical disorders, such as pulmonary disorders, neurodegenerative disorders, brain injury, psychiatric disor...
|
|
WO/2022/104156A1 |
Provided herein are biphasic dosing protocols for natalizumab therapy comprising both standard and extended interval dosing and subcutaneous administration.
|
|
WO/2022/102787A1 |
The present invention provides a method of producing astrocytes from pluripotent stem cells, said method comprising a step for expressing NEUROG2 gene in the pluripotent stem cells for less than three days.
|
|
WO/2022/103128A1 |
Disclosed is a composition for preventing or treating muscle diseases, containing stem cells in which GRO-α is expressed and/or GRO-α. GRO-α inhibits the death of muscle cells or myoblasts, and thus the present invention can be used a...
|
|
WO/2022/102784A1 |
Provided is a cell preparation capable of preventing a decrease in muscle mass. The cell preparation according to the present invention, which is to be used for preventing a decrease in muscle mass, comprises umbilical cord-derived cells.
|
|
WO/2022/102663A1 |
A coating agent comprising a polyrotaxane represented by formula (1). [In the formula, R1 represents a hydrogen atom or a methyl group; m is 1 to 2000; n is 10 to 500; (AA) represents a cyclodextrin moiety in which at least one hydroxyl ...
|
|
WO/2022/102722A1 |
The present disclosure includes: a pharmaceutical composition for treating pulmonary fibrosis, which contains hydroxypropyl cyclodextrin; and others.
|
|
WO/2022/103206A1 |
The present invention relates to a plasma radical solution and a method for preparing same and, more specifically, to a plasma radical solution and a method for preparing same, in which a plasma radical solution including radicals genera...
|
|
WO/2022/100570A1 |
Provided in the present disclosure is the use of a SARM1 enzyme activity inhibitor in the treatment of neurodegenerative diseases or neurological diseases or conditions, and in particular, provided in the present invention are a compound...
|
|
WO/2022/098192A1 |
The present invention relates to a composition for preventing, ameliorating or treating cachexia, comprising a complex extract of Cyperi rhizoma and Zanthoxyli pericarpium. The complex extract of the present invention exhibits the effect...
|
|
WO/2022/097727A1 |
The present invention provides a single-stranded antisense oligonucleotide or a pharmaceutically acceptable salt thereof for regulating the expression and/or function of the RPS25 gene. In the single-stranded antisense oligonucleotide, e...
|
|
WO/2022/099011A1 |
Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X1, X2, Ry, Rz, R1, R2, R3, and R4 are as defined herein. Also provided herein is...
|
|
WO/2022/096254A1 |
The invention relates to a method for reducing the population of at least one intestinal and/or gastrointestinal bacteria species, the method comprising the following steps: a) providing a biological specimen which comprises bacteria of ...
|
|
WO/2022/098051A1 |
The present invention relates to a novel peptide with anti-inflammatory and tissue regeneration actions, and a use thereof.
|
|
WO/2022/098642A1 |
Methods for treating diseases and conditions associated with phagocytosis deficiency and methods for treating cancer with phagocytosis activating agents and mitochondrial fission inhibitors, respectively, as monotherapy or in combination...
|
|
WO/2022/090457A1 |
Composition containing Nicotinamide and vitamin B6 are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical pur...
|
|
WO/2022/094617A1 |
Some embodiments of the invention include pseudotyped particles (e.g., pseudo typed exosomes, pseudotyped VSV, and pseudo typed lentiviruses) and modified cells. Other embodiments of the invention include compositions (e.g., pharmaceutic...
|
